Understand the importance of biomarkers in the management of your patients with NSCLC
oncogenic driver alterations identified1
of patients like yours may have an oncogenic alteration2,3
of patients like yours may have an oncogenic MET alteration4,5
These oncogenic driver mutations occur in approximately 50% of patients with NSCLC, including driver mutations such as KRAS, EGFR, ALK, MET and ROS1 alterations (25%, 15%, 5%, 3% and 2%, respectively*).2,3
1. Rossell R, Karachaliou N. Lancet 2016; 387:1354–1356.
2. Pakkala S, Ramalingam SS. JCI Insight 2018; 3:e120858.
3. Grosse A et al. Diagn Pathol 2019; 14:18.
4. Salgia R. Mol Cancer Ther 2017; 16:555–565.
5. Ikeda S et al. J Hematol Oncol 2018; 11:76.
6. Yoda S et al. Pharmacol Ther 2019; 193:20–30.